We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

New AI Technology Can Determine Best Type of Cancer Treatment

By Medimaging International staff writers
Posted on 23 Jan 2019
Print article
Image: New AI technology can help reduce the number of biopsies and surgeries for cancer patients (Photo courtesy of Case Western Reserve University).
Image: New AI technology can help reduce the number of biopsies and surgeries for cancer patients (Photo courtesy of Case Western Reserve University).
A team of researchers from Case Western Reserve University (Cleveland, OH, USA) is using artificial intelligence (AI) and smart-imaging computer technology for viewing routine medical images — MRIs, CAT scans, tissue biopsies — to determine the best type of cancer treatment.

In addition to detecting patterns beyond what the human eye can see, AI and computers can also determine the likelihood that a patient is going to respond to chemotherapy. A significant number of patients receive a cancer diagnosis, but also get over-treated and over-diagnosed. A recent study in the American Journal of Medicine found that 42% of new cancer patients lose their complete life savings in two years for treatment.

The researchers believe that a significant reduction can be brought about in the number of surgeries and of biopsies in patients who do not require them because they have benign nodules. Their research has been able to determine whether breast cancer patients, and more recently lung cancer patients, need chemotherapy. The technology would not reduce the number of jobs for pathologists or radiologists, but assist them and other clinicians.

Related Links:
Case Western Reserve University

Print article
Radcal
Italray

Channels

Copyright © 2000-2019 Globetech Media. All rights reserved.